Advanced search
Publication Cover
Cancer Investigation Volume 20, 2002 - Issue 2
Submit an article Journal homepage
246
Views
46
CrossRef citations to date
0
Altmetric
Original

Oxaliplatin: A Review of Evolving Concepts

Sridhar Mani Department of Oncology, Weiler Hospital/Montefiore Medical Center and the Albert Einstein Cancer Center of the Albert Einstein College of Medicine, Room 2S-63, 1825 Eastchester Road, Bronx, NY, 10461, U.S.A.
, M.D.,
Martin A. Graham Department of Clinical Pharmacokinetics and Drug Metabolism, Sanofi-Synthelabo, 9 Great Valley Parkway, Malvern, Pennsylvania
, Ph.D.,
David B. Bregman Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
, M.D., Ph.D.,
Percy Ivy Cancer Therapy Evaluation Program of the National Cancer Institute, Bethesda, Maryland, U.S.A.
, M.D. &
Stephen G. Chaney Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.
, Ph.D.
Pages 246-263 | Published online: 04 Sep 2002

Citations (46)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ruey-Kuen Hsieh, Tsu-Yi Chao, Wei-Shon Chen, Tsai-Shen Yang, Li-Tzong Chen, Po-Min Chen & Jin-Hwang Liu. (2004) Oxaliplatin Added to Simplified Bimonthly Low-Dose Leucovorin and 5-FU for Pretreated Advanced Colorectal Cancer Is Effective and Not Affected by Different Previous 5-FU Regimens. Cancer Investigation 22:2, pages 171-179.
Read now

Articles from other publishers (45)

Yu Feng, Zhenxiao Cao, An Xu & Hua Du. (2023) Evaluation of toxicity and mutagenicity of oxaliplatin on germ cells in an alternative in vivo model Caenorhabditis elegans. Food and Chemical Toxicology 178, pages 113902.
Crossref
Jingmiao Wang, Haizhong Zhang, Xiaoyan Yin & Yanrui Bian. (2022) Oxaliplatin Induces Immunogenic Cell Death in Human and Murine Laryngeal Cancer. Journal of Oncology 2022, pages 1-12.
Crossref
Ruby Maharjan, Jeong Uk Choi, Seho Kweon, Rudra Pangeni, Na Kyeong Lee, Seong Jin Park, Kwan-Young Chang, Jin Woo Park & Youngro Byun. (2022) A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy. Biomaterials 281, pages 121334.
Crossref
Maja T. Tomicic, Franziska Krämer, Alexandra Nguyen, Christian Schwarzenbach & Markus Christmann. (2021) Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14ARF-Mediated Sustained p53 Activation. Cancers 13:9, pages 2019.
Crossref
Dongfang Li, Yuying Kou, Yuan Gao, Shanshan Liu, Panpan Yang, Tomoka Hasegawa, Rongjian Su, Jie Guo & Minqi Li. (2021) Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS. Aging 13:3, pages 4242-4257.
Crossref
Sam J Egger, Matthew Ming Ki Chan, Qingwei Luo & Nicholas Wilcken. (2020) Platinum-containing regimens for triple-negative metastatic breast cancer. Cochrane Database of Systematic Reviews 2020:12.
Crossref
Maryam Salmani Jajaei & Sonia Rafiei. (2020) Preparation of drug delivery system based on poly (lactide-glycolide) and evaluation of parameters affecting its structure for cancer treatment. South African Journal of Chemical Engineering 33, pages 107-115.
Crossref
SABINE KARAM, VICTORIA GUTGARTS & ILYA GLEZERMAN. 2020. Onco-Nephrology. Onco-Nephrology 183 196.e7 .
G. Artiaga, A. Iglesias-Jiménez, E. Moreno-Gordaliza, M.L. Mena & M.M. Gómez-Gómez. (2019) Differences in binding kinetics, bond strength and adduct formation between Pt-based drugs and S- or N-donor groups: A comparative study using mass spectrometry techniques. European Journal of Pharmaceutical Sciences 132, pages 96-105.
Crossref
Loek A. W. de Jong, Fortuné M. K. Elekonawo, Philip R. de Reuver, Andre J. A. Bremers, Johannes H. W. de Wilt, Frank G. A. Jansman, Rob ter Heine & Nielka P. van Erp. (2019) Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. British Journal of Clinical Pharmacology 85:1, pages 47-58.
Crossref
Rachel M. McQuade, Vanesa Stojanovska, Joel C. Bornstein & Kulmira Nurgali. (2018) PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection. Pharmacological Research 137, pages 104-113.
Crossref
I. Buß, A. Hamacher, N. Sarin, M. U. Kassack & G. V. Kalayda. (2018) Relevance of copper transporter 1 and organic cation transporters 1–3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics 10:3, pages 414-425.
Crossref
Sam J Egger, Melina L Willson, Jenna Morgan, Harriet S Walker, Sue Carrick, Davina Ghersi & Nicholas Wilcken. (2017) Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews 2017:8.
Crossref
Jing Yang, Jing Chen & Zibiao Li. (2016) Structural Basis for the Structure–Activity Behaviour of Oxaliplatin and its Enantiomeric Analogues: A Molecular Dynamics Study of Platinum-DNA Intrastrand Crosslink Adducts. Australian Journal of Chemistry 69:4, pages 379.
Crossref
Fabio Arnesano, Alessandra Pannunzio, Mauro Coluccia & Giovanni Natile. (2015) Effect of chirality in platinum drugs. Coordination Chemistry Reviews 284, pages 286-297.
Crossref
Xiu Jun Wang, Yinyan Li, Lin Luo, Hongyan Wang, Zhexu Chi, Ai Xin, Xin Li, Jiaguo Wu & Xiuwen Tang. (2014) Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radical Biology and Medicine 70, pages 68-77.
Crossref
Hong-Yan Zhang, Chao Ji, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Wei-Chi Wang, Ling-Yun Zhang, Ping Xie & Peng-Ye Wang. (2014) Effects of pH on Oxaliplatin-Induced Condensation of Single DNA Molecules. Chinese Physics Letters 31:2, pages 028701.
Crossref
Hong-Yan Zhang, Yu-Ru Liu, Chao Ji, Wei Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Ling-Yun Zhang & Peng-Ye Wang. (2013) Oxaliplatin and Its Enantiomer Induce Different Condensation Dynamics of Single DNA Molecules. PLoS ONE 8:8, pages e71556.
Crossref
Linlin Wu, Changjun Man, Hong Wang, Xiaohe Lu, Qinghai Ma, Yu Cai & Wanshan Ma. (2012) PEGylated Multi-Walled Carbon Nanotubes for Encapsulation and Sustained Release of Oxaliplatin. Pharmaceutical Research 30:2, pages 412-423.
Crossref
C. L. King, S. Ramachandran, S. G. Chaney, L. Collins, J. A. Swenberg, K. E. deKrafft, W. Lin, L. Cicurel & M. Barbier. (2011) Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells. Cancer Chemotherapy and Pharmacology 69:3, pages 665-677.
Crossref
Satoshi Tanaka, Naoto Suzuki, Akira Mimura, Kaho Kurosawa, Yuriko Murai, Daisuke Saigusa, Makio Gamoh, Masuo Sato & Yoshihisa Tomioka. (2012) Serum Chlorine Level as a Possible Predictive Factor for Oxaliplatin-Induced Peripheral Neuropathy. Pharmacology & Pharmacy 03:01, pages 44-51.
Crossref
Amir Broomand, Elin Jerremalm, Jeffrey Yachnin, Hans Ehrsson & Fredrik Elinder. (2009) Oxaliplatin neurotoxicity – no general ion channel surface-charge effect. Journal of Negative Results in BioMedicine 8:1.
Crossref
Elin Jerremalm, Inger Wallin & Hans Ehrsson. (2009) New insights into the biotransformation and pharmacokinetics of oxaliplatin. Journal of Pharmaceutical Sciences 98:11, pages 3879-3885.
Crossref
Paola Milla, Mario Airoldi, Günther Weber, Anne Drescher, Ulrich Jaehde & Luigi Cattel. (2009) Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anti-Cancer Drugs 20:5, pages 396-402.
Crossref
L. Celio, C.N. Sternberg, R. Labianca, I. La Torre, V. Amoroso, C. Barone, G. Pinotti, S. Cascinu, F. Di Costanzo, G.L. Cetto & E. Bajetta. (2009) Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Annals of Oncology 20:6, pages 1062-1067.
Crossref
V. Hellberg, I. Wallin, S. Eriksson, E. Hernlund, E. Jerremalm, M. Berndtsson, S. Eksborg, E. S. J. Arner, M. Shoshan, H. Ehrsson & G. Laurell. (2008) Cisplatin and Oxaliplatin Toxicity: Importance of Cochlear Kinetics as a Determinant for Ototoxicity. JNCI Journal of the National Cancer Institute 101:1, pages 37-47.
Crossref
Chris H. Takimoto, Martin A. Graham, Graham Lockwood, Chee M. Ng, Andrew Goetz, Dennis Greenslade, Scot C. Remick, Sunil Sharma, Sridhar Mani, Ramesh K. Ramanathan, Timothy W. Synold, James H. Doroshow, Anne Hamilton, Daniel L. Mulkerin, Percy Ivy, Merrill J. Egorin & Jean L. Grem. (2007) Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function. Clinical Cancer Research 13:16, pages 4832-4839.
Crossref
Timothy W. Synold, Chris H. Takimoto, James H. Doroshow, David Gandara, Sridhar Mani, Scot C. Remick, Daniel L. Mulkerin, Anne Hamilton, Sunil Sharma, Ramesh K. Ramanathan, Heinz Josef Lenz, Martin Graham, Jeffrey Longmate, Bennett M. Kaufman & Percy Ivy. (2007) Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study. Clinical Cancer Research 13:12, pages 3660-3666.
Crossref
Britta Stordal, Nick Pavlakis & Ross Davey. (2007) Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review. Cancer Treatment Reviews 33:4, pages 347-357.
Crossref
Sona Krizkova, Vojtech Adam, Jitka Petrlova, Ondrej Zitka, Karel Stejskal, Josef Zehnalek, Bernd Sures, Libuse Trnkova, Miroslava Beklova & Rene Kizek. (2007) A Suggestion of Electrochemical Biosensor for Study of Platinum(II)-DNA Interactions. Electroanalysis 19:2-3, pages 331-338.
Crossref
Paula M. Fracasso, John A. Blessing, Kelly L. Molpus, Lisa M. Adler, Joel I. Sorosky & Peter G. Rose. (2006) Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology 103:2, pages 523-526.
Crossref
Lara Maria Pasetto, Mario Rosario D’Andrea, Alba Ariela Brandes, Elena Rossi & Silvio Monfardini. (2006) The development of platinum compounds and their possible combination. Critical Reviews in Oncology/Hematology 60:1, pages 59-75.
Crossref
Elin Jerremalm, Inger Wallin, Jeffrey Yachnin & Hans Ehrsson. (2006) Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate. European Journal of Pharmaceutical Sciences 28:4, pages 278-283.
Crossref
Gavin L Edwards, David St.C Black, Glen B Deacon & Laurence PG Wakelin. (2005) Effect of charge and surface area on the cytotoxicity of cationic metallointercalation reagents. Canadian Journal of Chemistry 83:6-7, pages 969-979.
Crossref
Shana S. Jacobs, Elizabeth Fox, Christopher Dennie, Lindsey B. Morgan, Cynthia L. McCully & Frank M. Balis. (2005) Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates. Clinical Cancer Research 11:4, pages 1669-1674.
Crossref
Aarif L. Shaikh, Vedavati G. Puranik & A.R.A.S. Deshmukh. (2005) Synthesis of cis bis-β-lactams via Staudinger cycloaddition reaction using C2-symmetric 1,2-diamines. Tetrahedron 61:9, pages 2441-2451.
Crossref
Anne Mathieu, Myriam Remmelink, Nicky D'Haene, Stanislas Penant, Jean‐François Gaussin, Rob Van Ginckel, Francis Darro, Robert Kiss & Isabelle Salmon. (2004) Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice. Cancer 101:8, pages 1908-1918.
Crossref
S. Goel, A. Bulgaru, H. Hochster, S. Wadler, W. Zamboni, M. Egorin, P. Ivy, L. Leibes, F. Muggia, G. Lockwood, E. Harvey, G. Renshaw & S. Mani. (2003) Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. Annals of Oncology 14:11, pages 1682-1687.
Crossref
W. Scheithauer & E. Van Cutsem. (2003) The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. Colorectal Disease 5, pages 36-44.
Crossref
Ramesh K. RamanathanJeffery W. ClarkNancy E. KemenyHeinz-Josef LenzKim O. GococoDaniel G. HallerEdith P. MitchellCarl G. Kardinal. (2003) Safety and Toxicity Analysis of Oxaliplatin Combined With Fluorouracil or as a Single Agent in Patients With Previously Treated Advanced Colorectal Cancer. Journal of Clinical Oncology 21:15, pages 2904-2911.
Crossref
Paula M. FracassoJohn A. BlessingMark A. MorganAnil K. SoodJames S. Hoffman. (2003) Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group Study. Journal of Clinical Oncology 21:15, pages 2856-2859.
Crossref
Chris H. TakimotoScot C. RemickSunil SharmaSridhar ManiRamesh K. RamanathanJames DoroshowAnne HamiltonDaniel MulkerinMartin GrahamGraham F. LockwoodPercy IvyMerrill EgorinBarbara SchulerDenis GreensladeAndrew GoetzRonald KnightRebecca ThomasBrian P. MonahanWilliam DahutJean L. Grem. (2003) Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study. Journal of Clinical Oncology 21:14, pages 2664-2672.
Crossref
Paula M Fracasso, John A Blessing, Judith Wolf, Thomas F Rocereto, Jonathan S Berek & Steven Waggoner. (2003) Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecologic Oncology 90:1, pages 177-180.
Crossref
Sandrine Faivre, Denise Chan, Richard Salinas, Barbara Woynarowska & Jan M. Woynarowski. (2003) DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochemical Pharmacology 66:2, pages 225-237.
Crossref
N. Farrell. 2003. Comprehensive Coordination Chemistry II. Comprehensive Coordination Chemistry II 809 840 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.